Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

140.71 +7.05 (+5.27%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 924,791
Open 141.00
Bid (Size) 140.65 (2)
Ask (Size) 140.75 (2)
Prev. Close 133.66
Today's Range 139.22 - 145.00
52wk Range 89.04 - 148.37
Shares Outstanding 98,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily

Performance

YTD
+6.82%
+6.82%
1 Month
+0.33%
+0.33%
3 Month
+0.65%
+0.65%
6 Month
+30.40%
+30.40%
1 Year
+35.87%
+35.87%

More News

Read More
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
Via MarketBeat
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Via Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Via Benzinga
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
Via Chartmill
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
Via Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.